A major challenge for healthcare providers and geneticists is to learn how SARS-CoV-2, the coronavirus that causes the COVID-19 disease, interacts with the human genome and to stratify populations in order to understand disease susceptibility, severity, and outcomes.
Axiom genotyping arrays and associated modules for human genotyping research can be used in various aspects of SARS-CoV-2 infection research:
|Category||Number of Markers*|
|SARS-CoV-2 Susceptibility Research Variant Module||>135,000|
|SARS-CoV-2 putative receptor variants||>1,200|
|Signaling pathway variants||>130,000|
|Variants on X-Chromosome||>60,000|
|SARS-CoV-2 Severity Research Module – Underlying conditions implicated in severity of SARS-CoV-2 infections||>16,000|
|Blood phenotypes and blood groups||>1,200|
|Lung function and COPD||>9,000|
|SARS-CoV-2 Immune Response and Therapeutic Treatment Research Variants Module||>24,000|
|ADME and protein markers for druggable targets||>6,000|
|Immunoglobulin and miRNA markers for vaccine research||>12,000|
|HLA/KIR markers for immune response research after vaccination||>9,000|
|Multi-ethnic Genome Wide Association Study (GWAS) Grid||>725,000|
|ACMG 59 Variants||>6,000|
|Functional coding-region variants including eQTL and loss-of-function variants||>24,000|
A marker may appear in more than one category.
For Research Use Only. Not for use in diagnostic procedures.